Cognition Disorders Clinical Trial
Official title:
Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer (CICARO)
Neurotoxic phenomena are among the most common and difficult to treat side effects of chemotherapy. The development of chemotherapy induced peripheral neuropathy (CIPN) is a well-recognized adverse reaction in the peripheral nervous system. Side effects of chemotherapy in the central nervous system, however, particularly changes of cognitive function (in non-medical literature referred to as "chemobrain") are diffuse and difficult to attribute to individual cytostatic drugs. The primary purpose of this study is to assess cognitive function in patients with ovarian and breast cancer before and after systemic chemotherapy with paclitaxel with standardized neuropsychological tests and compare the outcome to patients with benign gynecological tumors and breast cancer without chemotherapy treatment, respectively. Secondary parameters include the assessment of olfactory function, total neuropathy score and cytokine profiles.
Primary outcome parameter: compound score of standardized neuropsychological test Secondary parameters: - olfactory function (Sniffin Sticks) - total neuropathy score (TNS), reduced version (clinical examination, neurography of sural and peroneal nerve) - cytokine profiling from serum samples (ELISA) - quality of life (questionnaire) - depression screening (questionnaire) - symptoms of polyneuropathy (questionnaire) - symptoms of cognitive impairment (everyday memory test questionnaire) Assessment time points: - baseline (after surgical tumor resection and before chemotherapy) - follow up 1 (3 weeks after last chemotherapy cycle or 21 weeks (control patients)) - follow up 2 (optional; 1 year after chemotherapy completion) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02488720 -
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
|
||
| Recruiting |
NCT03544801 -
Renji Cerebral Small Vessel Disease Corhort Study
|
||
| Recruiting |
NCT02813434 -
Cerebral Amyloid Imaging Using Florbetapir (AV-45)
|
Phase 3 | |
| Completed |
NCT00400790 -
Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane
|
N/A | |
| Completed |
NCT00052091 -
Therapy for Depressed Elders With Thought Problems
|
Phase 3 | |
| Completed |
NCT00021866 -
Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy
|
N/A | |
| Completed |
NCT00267163 -
Brain Imaging and Mental Disorders of Aging Intervention
|
Phase 4 | |
| Not yet recruiting |
NCT04079075 -
Multiple Interventions to Prevent Cognitive Decline
|
N/A | |
| Terminated |
NCT03696082 -
A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines
|
N/A | |
| Completed |
NCT02918539 -
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
|
||
| Active, not recruiting |
NCT01708837 -
Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction
|
Phase 4 | |
| Completed |
NCT01290939 -
Bevacizumab and Lomustine for Recurrent GBM
|
Phase 3 | |
| Terminated |
NCT00548327 -
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
|
Phase 2 | |
| Unknown status |
NCT00256425 -
Cognitive Rehabilitation of Glioma Patients
|
Phase 3 | |
| Recruiting |
NCT03926351 -
High Dose Omega 3 in People at Risk for Dementia
|
Phase 2 | |
| Completed |
NCT02118571 -
Schizophrenia Cognition Scale Development
|
N/A | |
| Completed |
NCT01481961 -
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease
|
N/A | |
| Completed |
NCT00788918 -
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
|
N/A | |
| Completed |
NCT00564902 -
The Zeaxanthin and Visual Function Study
|
N/A | |
| Completed |
NCT00529581 -
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
|
Phase 2 |